Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Addressing guideline and policy changes during pragmatic clinical trials.

Curtis LH, Dember LM, Vazquez MA, Murray D, DeBar L, Staman KL, Septimus E, Mor V, Volandes A, Wells BL, Huang SS, Green BB, Coronado G, Meyers CM, Tuzzio L, Hernandez AF, Sugarman J.

Clin Trials. 2019 Aug;16(4):431-437. doi: 10.1177/1740774519845682. Epub 2019 May 14.

PMID:
31084378
2.

In Reply: "Impact of Targeted Temperature Management on ED Patients with Drug Overdose-Related Cardiac Arrest".

Khan S, Meyers CM, Bentley S, Manini AF.

J Med Toxicol. 2019 Jul;15(3):210-211. doi: 10.1007/s13181-019-00702-5. Epub 2019 Mar 5. No abstract available.

PMID:
30838508
3.

Pragmatic clinical trials offer unique opportunities for disseminating, implementing, and sustaining evidence-based practices into clinical care: Proceedings of a workshop.

Tuzzio L, Larson EB, Chambers DA, Coronado GD, Curtis LH, Weber WJ, Zatzick DF, Meyers CM.

Healthc (Amst). 2019 Mar;7(1):51-57. doi: 10.1016/j.hjdsi.2018.12.003. Epub 2018 Dec 26. Review.

4.

Impact of Targeted Temperature Management on ED Patients with Drug Overdose-Related Cardiac Arrest.

Khan S, Meyers CM, Bentley S, Manini AF.

J Med Toxicol. 2019 Jan;15(1):22-29. doi: 10.1007/s13181-018-0686-0. Epub 2018 Nov 8.

PMID:
30411236
5.

The CREST-E study of creatine for Huntington disease: A randomized controlled trial.

Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD; Huntington Study Group CREST-E Investigators and Coordinators.

Neurology. 2017 Aug 8;89(6):594-601. doi: 10.1212/WNL.0000000000004209. Epub 2017 Jul 12.

6.

Streamlining cardiovascular clinical trials to improve efficiency and generalisability.

Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R.

Heart. 2017 Aug;103(15):1156-1162. doi: 10.1136/heartjnl-2017-311191. Epub 2017 Apr 28. Review.

PMID:
28455296
7.

Freestanding Emergency Critical Care During the Aftermath of Hurricane Sandy: Implications for Disaster Preparedness and Response.

Smith SW, Jamin CT, Malik S, Abrukin L, Tupchong KM, Portelli I, Asaeda G, Prezant DJ, Wang B, Hu M, Goldfrank LR, Meyers CM.

Disaster Med Public Health Prep. 2016 Jun;10(3):496-502. doi: 10.1017/dmp.2016.84. Epub 2016 May 13.

PMID:
27174171
8.

Human Papillomavirus Vaccination Among Adults and Children in 5 US States.

Du P, Camacho F, McCall-Hosenfeld J, Lengerich E, Meyers CM, Christensen ND.

J Public Health Manag Pract. 2015 Nov-Dec;21(6):573-83. doi: 10.1097/PHH.0000000000000271.

9.

Silymarin for diabetic nephropathy: the challenges of botanical product research.

Meyers CM, Briggs JP.

Am J Kidney Dis. 2012 Dec;60(6):887-9. doi: 10.1053/j.ajkd.2012.09.002. No abstract available.

PMID:
23141996
10.

Safety and toxicity of saw palmetto in the CAMUS trial.

Avins AL, Lee JY, Meyers CM, Barry MJ; CAMUS Study Group.

J Urol. 2013 Apr;189(4):1415-20. doi: 10.1016/j.juro.2012.10.002. Epub 2012 Oct 9.

11.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group.

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

12.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group.

Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411. Epub 2011 Dec 28.

13.

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.

Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group.

Clin Trials. 2012 Feb;9(1):102-12. doi: 10.1177/1740774511427064. Epub 2011 Nov 4.

14.

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group.

JAMA. 2011 Sep 28;306(12):1344-51. doi: 10.1001/jama.2011.1364. Erratum in: JAMA. 2012 Jun 13;307(22):2374.

15.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-15. doi: 10.2215/CJN.04610511. Epub 2011 Sep 8.

16.

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW.

Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.

17.

The National Institutes of Health investment in research on botanicals.

Coates PM, Meyers CM.

Fitoterapia. 2011 Jan;82(1):11-3. doi: 10.1016/j.fitote.2010.11.013. Epub 2010 Nov 12. Review.

18.

The HALT polycystic kidney disease trials: design and implementation.

Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW.

Clin J Am Soc Nephrol. 2010 Jan;5(1):102-9. doi: 10.2215/CJN.04310709.

19.

Effect of dipyridamole plus aspirin on hemodialysis graft patency.

Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group.

N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.

20.

MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.

Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, Torres VE, Guay-Woodford LM, Meyers CM, Bennett WM; Consortium for Radiologic Imaging Studies Polycystic Kidney Disease.

Clin J Am Soc Nephrol. 2009 Apr;4(4):719-25. doi: 10.2215/CJN.03750708. Epub 2009 Apr 1.

21.

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.

Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access Consortium Study Group.

JAMA. 2008 May 14;299(18):2164-71. doi: 10.1001/jama.299.18.2164.

22.

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2007 Jan;2(1):112-20. Epub 2006 Nov 2.

23.

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2006 Jan;1(1):64-9. Epub 2005 Oct 26.

24.

Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.

Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC; CRISP Consortium.

J Am Soc Nephrol. 2007 Jul;18(7):2143-60. Epub 2007 Jun 20.

25.

Images in emergency medicine. Hemorrhagic pancreatitis.

Nelson BP, Meyers CM, Hermann LK.

Ann Emerg Med. 2007 Jun;49(6):734, 755. No abstract available.

PMID:
17512864
26.

Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP.

J Am Soc Nephrol. 2006 Nov;17(11):3013-9. Epub 2006 Oct 11.

27.

Volume progression in polycystic kidney disease.

Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators.

N Engl J Med. 2006 May 18;354(20):2122-30.

28.

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP; CRISP Consortium.

J Am Soc Nephrol. 2006 Mar;17(3):854-62. Epub 2006 Feb 1.

29.

Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.

Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.

Clin Trials. 2005;2(5):400-12.

PMID:
16317809
30.

Glomerular disease workshop.

Meyers CM, Geanacopoulos M, Holzman LB, Salant DJ.

J Am Soc Nephrol. 2005 Dec;16(12):3472-6. Epub 2005 Nov 2. Review.

31.

Workshop on late renal allograft dysfunction.

Meyers CM, Kirk AD.

Am J Transplant. 2005 Jul;5(7):1600-5. Review.

32.

Hepatitis C and renal disease: an update.

Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH.

Am J Kidney Dis. 2003 Oct;42(4):631-57. Review.

PMID:
14520615
33.
34.

New technologies for patients with end-stage renal disease: the US regulatory perspective.

Provost MC, Meyers CM.

Contrib Nephrol. 2001;(133):10-22. Review. No abstract available.

PMID:
11477743
35.

Autoreactive T-cell receptor expression in mouse chronic graft-vs-host disease.

Meyers CM, Birkos SJ.

Immunogenetics. 1999 Oct;50(1-2):74-8. No abstract available.

PMID:
10541810
37.

New insights into the pathogenesis of interstitial nephritis.

Meyers CM.

Curr Opin Nephrol Hypertens. 1999 May;8(3):287-92. Review.

PMID:
10456258
38.
40.

OEIS complex (omphalocele-exstrophy-imperforate anus-spinal defects) in monozygotic twins.

Lee DH, Cottrell JR, Sanders RC, Meyers CM, Wulfsberg EA, Sun CC.

Am J Med Genet. 1999 May 7;84(1):29-33.

PMID:
10213043
41.
42.

Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus.

Bick DP, McCorkle D, Stanley WS, Stern HJ, Staszak P, Berkovitz GD, Meyers CM, Kelley RI.

Prenat Diagn. 1999 Jan;19(1):68-71. Review.

PMID:
10073912
43.

Correlation of prenatal ultrasound diagnosis and pathologic findings in fetal anomalies.

Sun CC, Grumbach K, DeCosta DT, Meyers CM, Dungan JS.

Pediatr Dev Pathol. 1999 Mar-Apr;2(2):131-42.

PMID:
9949219
44.

The nephritogenic T cell response in murine chronic graft-versus-host disease.

Meyers CM, Tomaszewski JE, Glass JD, Chen CW.

J Immunol. 1998 Nov 15;161(10):5321-30.

45.

Antenatal diagnosis of lethal skeletal dysplasias.

Tretter AE, Saunders RC, Meyers CM, Dungan JS, Grumbach K, Sun CC, Campbell AB, Wulfsberg EA.

Am J Med Genet. 1998 Feb 17;75(5):518-22.

PMID:
9489797
46.

46,XY,i(21q) identified by maternal serum screening.

Meyers CM, Ghori S, Roberson AE, Blitzer MG, Cohen MM.

Md Med J. 1997 Feb;46(2):88-9.

PMID:
9029908
47.
48.

Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form.

Meyers CM, Boughman JA, Rivas M, Wilroy RS, Simpson JL.

Am J Med Genet. 1996 Jun 28;63(4):518-24. Review.

PMID:
8826428
49.

T-cell regulation of renal immune responses.

Meyers CM.

Curr Opin Nephrol Hypertens. 1995 May;4(3):270-6. Review.

PMID:
7648225
50.

Supplemental Content

Loading ...
Support Center